Dianhydrogalactitol: Clinical Trials

6 trials of Dianhydrogalactitol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Recruiting 1, Withdrawn 1
Phase 12Completed 1, Withdrawn 1
Phase 32Recruiting 1, Terminated 1

Follow Dianhydrogalactitol: new trials by email Literature Review of Dianhydrogalactitol trials Research Report on Dianhydrogalactitol

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
VAL-083, Dianhydrogalactitol - Ovarian Cancer
Phase 1 / Phase 2WithdrawnDelMar Pharmaceuticals, Inc.2021-03-012019-10-18
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide, Lomustine, Regorafenib - Glioblastoma
Phase 2 / Phase 3RecruitingGlobal Coalition for Adaptive Research22502019-07-302026-11-02
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
VAL-083 (Dianhydrogalactitol) - Glioma, Glioblastoma
Phase 2CompletedKintara Therapeutics, Inc.292017-12-172025-09-04
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine - Glioblastoma Multiforme, Glioblastoma
Phase 3TerminatedDelMar Pharmaceuticals, Inc.22017-10-272025-09-04
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
VAL-083, Dianhydrogalactitol - Glioma, Glioblastoma
Phase 2CompletedKintara Therapeutics, Inc.1182017-01-202025-08-29
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
VAL-083 (Dianhydrogalactitol) - Glioma, Glioblastoma
Phase 1 / Phase 2CompletedKintara Therapeutics, Inc.552011-10-012025-08-29

Conditions studied

Glioblastoma (5)  ·  Brain Neoplasms (4)  ·  Glioma (4)  ·  Ovarian Neoplasms (1)  ·  Recurrence (1)

Sponsors

Kintara Therapeutics, Inc. (3)  ·  DelMar Pharmaceuticals, Inc. (2)  ·  Global Coalition for Adaptive Research (1)

Countries

United States (5)  ·  Australia (1)  ·  Canada (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Switzerland (1)

Top investigators

Nicholas Butowski, M.D. (2)  ·  Barbara O'Brien, M.D. (1)  ·  Bradley J Monk, M.D. (1)  ·  Chen Zhong-ping, M.D., Ph.D. (1)  ·  Gerald Falchook, M.D. (1)  ·  Howard A Burris, M.D. (1)  ·  Manish Patel, M.D. (1)  ·  Sani Kizilbash, M.D. (1)  ·  Tim Cloughesy, MD (1)

Results publications

PMID 38773224, PMID 41385182, PMID 41980234